vation and conversion facility; also in Clark County
, NV. The Company is awaiting final State approval, expected later this year, for both the dispensary and the cultivation facility. If both licenses are granted, and allowing some time for construction, GrowBLOX expects to be generating revenues from the cultivation and sale of legal medical cannabis in the second half of 2015.
Mr. Ellins commented, "We anticipate getting a response on our application for two additional dispensaries in the first quarter of 2015, although the timing of a response is outside of our control. We are very excited about the prospect of adding to our Nevada presence. This is part of our strategy of securing the rights to dispensaries and grow-sites nationwide. As we've previously announced, we have similar expansion efforts in Florida, Illinois, New York and elsewhere. We look forward to updating our shareholders as we continue to execute on our business plan."
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc., is a research and biotechnical company that has developed proprietary indoor growing chambers specifically designed for medical cannabis cultivation. The GrowBLOXTM chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product. The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions. http://www.gbsciences.com
Except for historical information contained herein, the statements in this
Page: 1 2 3 Related biology technology :1
|SOURCE GrowBLOX Sciences, Inc.|
Copyright©2014 PR Newswire.
All rights reserved
. Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research2
. VG Life Sciences, Inc. Update on Phase I Cancer Study3
. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update4
. Pressure BioSciences, Inc. to Discuss Third Quarter 2013 Financial Results and Provide a Business Update5
. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors6
. Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results7
. Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media8
. MELA Sciences, Inc., a Leader in the Fight Against Melanoma, Participates in the American Society of Dermatologic Surgery Annual Meeting9
. VG Life Sciences, Inc. Closes on $2,235,000 from Private Fund10
. Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo11
. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference